← feed

Is NCT03216278 results overdue?

Yes — results are overdue. Primary completion was 2018-05-22; the FDAAA-801 reporting deadline (2019-05-22) passed 2633 days ago and no results are posted on ClinicalTrials.gov.

The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions

NCT IDNCT03216278 ↗
SponsorAstraZeneca (INDUSTRY)
Public issuerASTRAZENECA PLC — AZN (CIK 0000901832) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2018-05-22 (ACTUAL)
Reporting deadline2019-05-22 (completion + 365d)
Days overdue2633
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 42b88b1b4a26d71f… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03216278. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →